Showing results (101-110 of 559) with videos related to
Sort By:
Pageof 56
Journal of the American College of Cardiology|September 6, 2008
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysisRoberto R Giraldez, Robert P Giugliano, Satishkumar Mohanavelu, et al.The American Journal of Cardiology|August 30, 2005
C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)Nazanin Moghbeli, Ajay J Kirtane, Kausik K Ray, et al.JACC. Cardiovascular Interventions|June 21, 2014
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38)Jacob A Udell, Eugene Braunwald, Elliott M Antman, et al.Journal of the American College of Cardiology|October 22, 2013
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)Payal Kohli, Jacob A Udell, Sabina A Murphy, et al.Journal of Thrombosis and Thrombolysis|October 6, 2007
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16Benjamin A Olenchock, Stephen D Wiviott, Sabina A Murphy, et al.Circulation|December 23, 2009
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38Elizabeth M Mahoney, Kaijun Wang, Suzanne V Arnold, et al.Journal of the American College of Cardiology|December 4, 2014
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trialMarc P Bonaca, Benjamin M Scirica, Eugene Braunwald, et al.European Heart Journal|December 25, 2010
Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trialBenjamin M Scirica, Marc S Sabatine, Petr Jarolim, et al.Journal of the American College of Cardiology|May 8, 2010
Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin IMarc Bonaca, Benjamin Scirica, Marc Sabatine, et al.The American Journal of Cardiology|September 6, 2011
Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial)James R Harkness, David A Morrow, Eugene Braunwald, et al.Pageof 56